Zymeworks enters into license agreement with Iconic Therapeutics for ZymeLink
Zymeworks announced that it has entered into a licensing agreement that grants Iconic Therapeutics non-exclusive rights to Zymeworks' proprietary ZymeLink antibody-drug conjugate, or ADC, platform for the development of its ICON-2 Tissue Factor ADC for cancer. This is the first collaboration leveraging the ZymeLink platform and represents Zymeworks' third technology platform licensed to a collaborator. Under the terms of the agreement, Zymeworks will be eligible to receive development and commercial milestone payments and tiered royalties on worldwide net sales. The agreement also provides Zymeworks co-promotion rights with increased royalties for products developed using the Iconic ADC program. If Iconic outlicenses the program, in lieu of co-promotion rights, Zymeworks will receive a share of the revenue Iconic receives from any partners as well as tiered royalties on worldwide net sales.